177Lu-DOTATATE (PRRT) in the treatment of patients with gastroenteropancreatic neuroendocrine tumors (GEPNETs) versus other tumors
Por:
Jimenez-Fonseca, P, Pubul, V, Bello, P, Riesco-Martinez, M, Aller, J, Alonso, P, Caballero, E, Custodio, A, Centeno, R, Teulee, A, Casanovas, M and Carmona-Bayonas, A
Publicada:
1 mar 2022
Resumen:
Filiaciones:
Jimenez-Fonseca, P:
Hosp Univ Cent Asturias, Dept Med Oncol, ISPA, Oviedo, Spain
Pubul, V:
Hosp Univ Santiago Compostela, Dept Nucl Med, Santiago, Spain
Bello, P:
Hosp Univ La Fe, Dept Nucl Med, Valencia, Spain
Riesco-Martinez, M:
Hosp Univ Doce Octubre, Dept Med Oncol, Madrid, Spain
Aller, J:
Hosp Univ Puerta de Hierro, Dept Endocrinol, Madrid, Spain
Alonso, P:
Hosp Univ Getafe, Dept Nucl Med, Madrid, Spain
:
Hosp Univ Doctor Peset, Dept Nucl Med, Valencia, Spain
Custodio, A:
Hosp Univ La Paz, Dept Med Oncol, Madrid, Spain
Centeno, R:
Hosp Univ Gregorio Maranon, Dept Endocrinol, Madrid, Spain
Teulee, A:
Hosp Univ Duran & Reynalds, Dept Med Oncol, ICO, CIBERONC, Lhospitalet De Llobregat, Spain
Casanovas, M:
Hosp Univ Puerta de Hierro, Dept Nucl Med, Madrid, Spain
Carmona-Bayonas, A:
Hosp Gen Univ Morales Meseguer, UMU, IMIB, Dept Med Oncol, Murcia, Spain
|